You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

GDP Chemotherapy

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Large Cell Lymphoma, Diffuse, Relapsed Cancer, Refractory Cancer Trial (AutoSCT, GDP, Epcoritamab)

Not yet recruiting
  • Large Cell Lymphoma, Diffuse
  • +2 more
  • AutoSCT
  • +2 more
  • (no location specified)
May 10, 2023

Lymphoma, Non-Hodgkin's Trial in Toronto (Obinutuzumab, Gemcitabine, Dexamethasone)

Completed
  • Lymphoma, Non-Hodgkin's
  • Toronto, Ontario, Canada
    Princess Margaret Cancer Centre
Apr 11, 2021

Hodgkin Lymphoma Trial (Gemcitabine, Dexamethasone, Cisplatin)

Not yet recruiting
  • Hodgkin Lymphoma
  • (no location specified)
May 9, 2022

Diffuse Large B-cell Lymphoma Trial in Chapel Hill (Polatuzumab vedotin (PV), Rituximab, Hyaluronidase)

Not yet recruiting
  • Diffuse Large B-cell Lymphoma
  • Polatuzumab vedotin (PV)
  • +6 more
  • Chapel Hill, North Carolina
    Lineberger Comprehensive Cancer Center
Aug 9, 2022

Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T Cell Lymphoma, ALK-negative Anaplastic Large Cell

Unknown status
  • Peripheral T-Cell Lymphoma, Not Otherwise Specified
  • +5 more
  • CEOP/IVE/GDP chemotherapy regimen
  • CEOP chemotherapy regimen for 6 cycles
  • Fuzhou, Fujian, China
  • +3 more
Mar 7, 2020

Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma Trial in Changchun (Rituximab,

Recruiting
  • Peripheral T-Cell Lymphoma, Not Otherwise Specified
  • Angioimmunoblastic T-cell Lymphoma
  • Changchun, Jilin, China
    The First Bethune Hospital of Jilin University
Apr 7, 2023

Refractory T-Cell Lymphoma, Relapsed T-Cell Lymphoma Trial in Italy (Daratumumab)

Active, not recruiting
  • Refractory T-Cell Lymphoma
  • Relapsed T-Cell Lymphoma
  • Bari, Italy
  • +6 more
Aug 1, 2022

B-cell Lymphoma Trial in Belgium, France (selinexor, Rituximab, Dexamethasone)

Completed
  • B-cell Lymphoma
  • Bruxelles, Belgium
  • +7 more
Dec 6, 2021

Lymphoma, Non-Hodgkin Trial in Worldwide (Standard of Care, JCAR017)

Active, not recruiting
  • Lymphoma, Non-Hodgkin
  • Standard of Care
  • JCAR017
  • Phoenix, Arizona
  • +78 more
Jan 13, 2023

Non-Hodgkin Lymphoma Trial in Worldwide (Tisagenlecleucel after optional bridging and lymphodepleting chemo, Platinum-based

Active, not recruiting
  • Non-Hodgkin Lymphoma
  • Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy
  • Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)
  • La Jolla, California
  • +66 more
Jan 6, 2023

Lymphoma Trial in Canada (cisplatin, dexamethasone, gemcitabine HCl)

Completed
  • Lymphoma
  • Calgary, Alberta, Canada
  • +12 more
Apr 7, 2020

nk/T-cell Lymphoma, Newly Diagnosed, Advanced Lymphoma Trial in Beijing (XPO1 inhibitor)

Recruiting
  • nk/T-cell Lymphoma
  • +2 more
  • XPO1 inhibitor
  • Beijing, Haidian, China
    ChinaPLAGH
Apr 18, 2023

Relapsed or Refractory B-cell Lymphoma Trial in Shanghai (SR-GDP)

Not yet recruiting
  • Relapsed or Refractory B-cell Lymphoma
  • Shanghai, Shanhai, China
    Ruijin Hospital
Sep 29, 2023

Magnetic Resonance Imaging:A Window to Anthracycline Toxicity

Active, not recruiting
  • Cardiac Complications
    • Hartford, Connecticut
      Olga H Toro-Salazar
    Jan 11, 2022

    Diffuse Large B Cell Lymphoma, CD79A Gene Mutation, CD79B Gene Mutation Trial in Zhengzhou (Rituximab, Zanubrutinib,

    Recruiting
    • Diffuse Large B Cell Lymphoma
    • +2 more
    • Zhengzhou, Henan, China
      Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZho
    Jan 22, 2022

    Relapsed/Refractory Diffuse Large B-cell Lymphoma Trial in Worldwide (Selinexor (combination therapy), Placebo matching for

    Recruiting
    • Relapsed/Refractory Diffuse Large B-cell Lymphoma
    • Selinexor (combination therapy)
    • +7 more
    • Chandler, Arizona
    • +51 more
    May 6, 2022

    Lymphoma Trial in Australia, Canada, United States (rituximab, cisplatin, cytarabine)

    Completed
    Has Results
    • Lymphoma
    • rituximab
    • +4 more
    • Chicago, Illinois
    • +26 more
    Mar 30, 2020

    Dentists' Attitudes Towards Pharmacological Management of Acute

    Recruiting
    • Pain Management
    • Survey
    • Malmö, Skåne, Sweden
      Malmö University
    Jun 15, 2023

    Pain in Patients Treated for Advanced Cancer

    Recruiting
    • Advanced Cancer
    • one music therapy session
    • Montpellier, France
      Institut du Cancer de Montpellier
    Jun 10, 2022

    NSCLC Trial in Charleston (Sotorasib and Tarloxotinib)

    Recruiting
    • Non-Small Cell Lung Cancer
    • Sotorasib and Tarloxotinib
    • Charleston, South Carolina
      Hollings Cancer Center at Medical University of South Carolina
    Mar 28, 2022

    Lymphoma, B-Cell Trial in Vancouver, Toronto, Montreal (Venetoclax, RiTUXimab Injection, Rituximab SC)

    Recruiting
    • Lymphoma, B-Cell
    • Vancouver, British Columbia, Canada
    • +2 more
    Jan 24, 2022

    Advance Care Planning, Multimorbidity, Old Age; Debility Trial in Rotterdam (Advance Care Planning interview)

    Recruiting
    • Advance Care Planning
    • +6 more
    • Advance Care Planning interview
    • Rotterdam, Noord Holland, Netherlands
      Erasmus MC
    Jan 10, 2022

    Lymphoma, B-Cell Trial in Worldwide (inotuzumab ozogamicin+rituximab +cyclophosphamide+vincristine+prednisone, inotuzumab

    Completed
    Has Results
    • Lymphoma, B-Cell
    • inotuzumab ozogamicin+rituximab +cyclophosphamide+vincristine+prednisone
    • inotuzumab ozogamicin+rituximab+gemcitabine+cisplatinum+dexamethasone
    • Gainesville, Florida
    • +27 more
    Jun 13, 2019

    Treatment, Peripheral T-cell Lymphoma Trial in Beijing (liposomal mitoxantrone HCl, gemcitabine, dexamethasone, and cisplatin)

    Recruiting
    • Treatment
    • Peripheral T-cell Lymphoma
    • liposomal mitoxantrone hydrochloride, gemcitabine, dexamethasone, and cisplatin
    • Beijing, China
    • +4 more
    Jun 28, 2022

    Cancer-related Fatigue, Light; Therapy, Complications Trial in Eskisehir (White Light Application)

    Completed
    • Cancer-related Fatigue
    • Light; Therapy, Complications
    • White Light Application
    • Eskisehir, Turkey
      Eskisehir Osmangazi University Faculty of Medicine
    Aug 11, 2021